Leadership in Ophthalmology

Our Team

We love building products for you

John Higuchi

CEO

Higuchi has managed Aciont since the advancement of its ophthalmology research program in noninvasive therapeutics.  John is a board member and co-founder, Lipocine (Nasdaq: LPCN), a late clinical staged oral drug delivery Utah company focused on men's (testosterone replacement therapy, a pending NDA under review) and women's health (e.g., preterm birth prevention drug positioned to enter phase 3) and a co-founder, board member of Spriaso, LLC, a Utah company with an FDA approved respiratory drug expected to have a commercial launch before the Summer of 2018.  John has a BSci Chemistry, Hope College and MBA and MS in Information Systems, The George Washington University.

Kongnara Papangkorn

Vice President, Product Development

Kong has supervised all ophthalmology research projects and the clinical study of DSP-Visulex and has been a co-investigator of both NIH and DOD funded biopharmaceutical research projects.  Kong has expertise in drug delivery and biomaterials and holds a BSci Pharmaceutical Science, Chulalongkorn University

and Ph.D. in Pharmaceutics and Pharmaceutical Chemistry, University of Utah.

Balbir S. Brar

Vice President, Research and Development

Brar has extensive commercial pharmaceutical development experience which includes 16 years at Allergan (NYSE:AGN) as VP Drug safety, metabolism, pharmacokinetics, life sciences and drug candidate optimization.  There he has managed over 20 projects in all major therapeutic areas including Alphagan, Lumigan, Tazarotene and Botox. Other experiences include being Sr. Director of Drug Safety at GSK & Wyeth.  Bal has a Ph.D. in Toxicology and Pathology, Rutgers University.

Our Team

We love building products for you

William I. Higuchi

Founder and CTO

Higuchi is a world-renowned leader in the field of drug delivery with more than 100 PhD students and 100 post-doctoral trained professionals and with more than 40 years of experience in the research and development of noninvasive therapeutics and medical devices.  Bill's academic experiences included distinguished positions with the respective pharmaceutics teaching and research departments at the University of Michigan and The University of Utah.  Bill was co-founder/chairman of TheraTech, Inc., now a subsidiary of Allergan (NYSE:AGN) and co-founder/chairman of Lipocine Inc., an oral lipid based drug delivery company all located in Salt Lake City, Utah.   Dr. Higuchi served as the editor for the International Journal of Pharmaceutics and The Journal of Pharmaceutical Sciences.